SubHero Banner

Monjuvi ® (tafasitamab-cxix) – New drug approval

July 31, 2020 - Morphosys and Incyte announced the FDA approval of Monjuvi (tafasitamab-cxix), in combination with Revlimid® (lenalidomide) for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) not otherwise specified, including DLBCL arising from low grade lymphoma, and who are not eligible for autologous stem cell transplant (ASCT).

Download PDF